Top

Current Diabetes Reports

Published in:

01-12-2019 | Insulins | Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Diabetic Gastroparesis and Glycaemic Control

Authors: Ryan Jalleh, Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz

Published in: Current Diabetes Reports | Issue 12/2019

Abstract

Purpose of Review

Gastroparesis is an important complication of diabetes that may have a major impact on the quality of life as a result of upper gastrointestinal symptoms and impaired glycaemic control. Current management strategies include optimising blood glucose control, dietary modifications and supportive nutrition. Pharmacologic approaches with drugs that have prokinetic and/or antiemetic effects are also used widely; however, current available treatments have major limitations. There is increasing recognition that the rate of gastric emptying (GE) is a key determinant of the glycaemic response to a meal.

Recent Findings

There is ongoing uncertainty regarding the impact of longstanding hyperglycaemia on GE, which requires clarification. New diagnostic techniques have been developed to better characterise the mechanisms underlying gastroparesis in individual patients, and these have the potential to lead to more personalised therapy.

Summary

Management of gastroparesis is complex and suboptimal; novel approaches are desirable. This review summarises recent advances in the understanding of diabetic gastroparesis, with an emphasis on the current therapies that influence GE, and the bidirectional relationship between glycaemic control and GE.

Yu D, Ramsey FV, Norton WF, Norton N, Schneck S, Gaetano T, et al. The burdens, concerns, and quality of life of patients with gastroparesis. Dig Dis Sci. 2017;62(4):879–93. https://doi.org/10.1007/s10620-017-4456-7.CrossRefPubMed

Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225–33. https://doi.org/10.1053/j.gastro.2008.12.047.CrossRefPubMed

NIDDK. Gastroparesis Clinical Research Consortium (GpCRC). 2019. https://repository.niddk.nih.gov/studies/gpcrc/. Accessed 3 Aug 2019 2019.

Wadhwa V, Mehta D, Jobanputra Y, Lopez R, Thota PN, Sanaka MR. Healthcare utilization and costs associated with gastroparesis. World J Gastroenterol. 2017;23(24):4428–36. https://doi.org/10.3748/wjg.v23.i24.4428.CrossRefPubMedPubMedCentral

Syed AR, Wolfe MM, Calles-Escandon J. Epidemiology and diagnosis of gastroparesis in the United States: a population-based study. J Clin Gastroenterol. 2019. https://doi.org/10.1097/MCG.0000000000001231.PubMed

Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR 3rd. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012;18(1):34–42. https://doi.org/10.5056/jnm.2012.18.1.34.CrossRefPubMedPubMedCentral

Bharucha AE, Batey-Schaefer B, Cleary PA, Murray JA, Cowie C, Lorenzi G, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology. 2015;149(2):330–9. https://doi.org/10.1053/j.gastro.2015.05.007.PubMedPubMedCentral

Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2011;9(1):5–12; quiz e7. doi:https://doi.org/10.1016/j.cgh.2010.09.022.PubMed

Samsom M, Roelofs JM, Akkermans LM, van Berge Henegouwen GP, Smout AJ. Proximal gastric motor activity in response to a liquid meal in type I diabetes mellitus with autonomic neuropathy. Dig Dis Sci. 1998;43(3):491–6. https://doi.org/10.1023/a:1018894520557.CrossRefPubMed

10.

Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986;90(6):1919–25. https://doi.org/10.1016/0016-5085(86)90262-3.CrossRefPubMed

11.

He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology. 2001;121(2):427–34.PubMed

12.

Sanders KM, Ward SM, Koh SD. Interstitial cells: regulators of smooth muscle function. Physiol Rev. 2014;94(3):859–907. https://doi.org/10.1152/physrev.00037.2013.CrossRefPubMedPubMedCentral

13.

Yang S, Wu B, Sun H, Sun T, Han K, Li D et al. Impaired insulin/IGF-1 is responsible for diabetic gastroparesis by damaging myenteric cholinergic neurones and interstitial cells of Cajal. Biosci Rep. 2017;37(5). doi:https://doi.org/10.1042/BSR20170776.

14.

Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005;9(1):102–8. https://doi.org/10.1016/j.gassur.2004.10.001.CrossRefPubMed

15.

Iwasaki H, Kajimura M, Osawa S, Kanaoka S, Furuta T, Ikuma M, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol. 2006;41(11):1076–87. https://doi.org/10.1007/s00535-006-1909-8.CrossRefPubMed

16.

Grover M, Bernard CE, Pasricha PJ, Lurken MS, Faussone-Pellegrini MS, Smyrk TC, et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil. 2012;24(6):531–9, e249. https://doi.org/10.1111/j.1365-2982.2012.01894.x.

17.

Grover M, Farrugia G, Lurken MS, Bernard CE, Faussone-Pellegrini MS, Smyrk TC, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. 2011;140(5):1575–85 e8. https://doi.org/10.1053/j.gastro.2011.01.046.

18.

Choi KM, Kashyap PC, Dutta N, Stoltz GJ, Ordog T, Shea Donohue T et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology. 2010;138(7):2399–409, 409 e1. doi:https://doi.org/10.1053/j.gastro.2010.02.014.PubMedCentral

19.

Choi KM, Gibbons SJ, Nguyen TV, Stoltz GJ, Lurken MS, Ordog T et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology. 2008;135(6):2055–64, 64 e1–2. doi:https://doi.org/10.1053/j.gastro.2008.09.003.PubMedCentral

20.

Bernard CE, Gibbons SJ, Mann IS, Froschauer L, Parkman HP, Harbison S, et al. Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil. 2014;26(9):1275–84. https://doi.org/10.1111/nmo.12389.

21.

Kreuch D, Keating DJ, Wu T, Horowitz M, Rayner CK, Young RL. Gut mechanisms linking intestinal sweet sensing to glycemic control. Front Endocrinol (Lausanne). 2018;9:741. doi:https://doi.org/10.3389/fendo.2018.00741.

22.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–39. https://doi.org/10.1152/physrev.00034.2006.CrossRef

23.

Young RL, Chia B, Isaacs NJ, Ma J, Khoo J, Wu T, et al. Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes. Diabetes. 2013;62(10):3532–41. https://doi.org/10.2337/db13-0581.PubMedPubMedCentral

24.

Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26(1):3–10. https://doi.org/10.1097/MED.0000000000000448.CrossRefPubMed

25.

Christofides ND. Importance of the jejunal hormone motilin. J Clin Pathol Suppl (Assoc Clin Pathol). 1978;8:51–7. https://doi.org/10.1136/jcp.s1-8.1.51.CrossRef

26.

Sanger GJ, Wang Y, Hobson A, Broad J. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol. 2013;170(7):1323–32. https://doi.org/10.1111/bph.12075.CrossRefPubMedPubMedCentral

27.

Achem-Karam SR, Funakoshi A, Vinik AI, Owyang C. Plasma motilin concentration and interdigestive migrating motor complex in diabetic gastroparesis: effect of metoclopramide. Gastroenterology. 1985;88(2):492–9. https://doi.org/10.1016/0016-5085(85)90512-8.CrossRefPubMed

28.

Peeters TL, Muls E, Janssens J, Urbain JL, Bex M, Van Cutsem E, et al. Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Gastroenterology. 1992;102(1):97–101. https://doi.org/10.1016/0016-5085(92)91788-6.CrossRefPubMed

29.

Levin F, Edholm T, Schmidt PT, Gryback P, Jacobsson H, Degerblad M, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006;91(9):3296–302. https://doi.org/10.1210/jc.2005-2638.CrossRefPubMed

30.

Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med. 1991;18(4):229–34. https://doi.org/10.1007/bf00186645.CrossRefPubMed

31.

Horowitz M, Jones KL, Rayner CK, Read NW. ‘Gastric’ hypoglycaemia--an important concept in diabetes management. Neurogastroenterol Motil. 2006;18(6):405–7. https://doi.org/10.1111/j.1365-2982.2006.00804.x.CrossRefPubMed

32.

Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil. 2006;18(6):433–40. https://doi.org/10.1111/j.1365-2982.2006.00800.x.CrossRefPubMed

33.

Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med. 1995;36(12):2220–8.PubMed

34.

Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33(11):675–80.PubMed

35.

MacGregor IL, Gueller R, Watts HD, Meyer JH. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology. 1976;70(2):190–6.PubMed

36.

Samsom M, Akkermans LM, Jebbink RJ, van Isselt H, vanBerge-Henegouwen GP, Smout AJ. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut. 1997;40(5):641–646. doi:https://doi.org/10.1136/gut.40.5.641.PubMedPubMedCentral

37.

Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1):60–6. https://doi.org/10.1016/s0016-5085(97)70080-5.CrossRefPubMed

38.

Izzy M, Lee M, Johns-Keating K, Kargoli F, Beckoff S, Chun K, et al. Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. Diabetes Res Clin Pract. 2018;135:45–9. https://doi.org/10.1016/j.diabres.2017.10.016.PubMed

39.

Reddy S, Ramsubeik K, Vega KJ, Federico J, Palacio C. Do HbA1C levels correlate with delayed gastric emptying in diabetic patients? J Neurogastroenterol Motil. 2010;16(4):414–7. https://doi.org/10.5056/jnm.2010.16.4.414.CrossRefPubMedPubMedCentral

40.

Merio R, Festa A, Bergmann H, Eder T, Eibl N, Stacher-Janotta G, et al. Slow gastric emptying in type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care. 1997;20(3):419–23. https://doi.org/10.2337/diacare.20.3.419.CrossRefPubMed

41.

Schvarcz E, Palmer M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med. 1993;10(7):660–3. https://doi.org/10.1111/j.1464-5491.1993.tb00141.x.CrossRefPubMed

42.

Russo A, Stevens JE, Chen R, Gentilcore D, Burnet R, Horowitz M, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab. 2005;90(8):4489–95. https://doi.org/10.1210/jc.2005-0513.

43.

Sharma D, Morrison G, Joseph F, Purewal TS, Weston PJ. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia. 2011;54(11):2768–70. https://doi.org/10.1007/s00125-011-2282-6.CrossRefPubMed

44.

Calles-Escandon J, Koch KL, Hasler WL, Van Natta ML, Pasricha PJ, Tonascia J, et al. Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: an open-label pilot prospective study. PLoS One. 2018;13(4):e0194759. https://doi.org/10.1371/journal.pone.0194759.CrossRefPubMedPubMedCentral

45.

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603. https://doi.org/10.2337/dci19-0028.PubMed

46.

Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(3):151–9.PubMed

47.

Shao ZM, Yao JF, Chen J, Yu ZW, Yu XF, Zheng JJ, et al. Effects of rehabilitation management on gastric emptying function in older adults with diabetes. Genet Mol Res. 2014;13(4):9244–52. https://doi.org/10.4238/2014.January.24.5.CrossRefPubMed

48.

Bharucha AE, Kudva Y, Basu A, Camilleri M, Low PA, Vella A, et al. Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes. Clin Gastroenterol Hepatol. 2015;13(3):466–76 e1. https://doi.org/10.1016/j.cgh.2014.06.034.PubMed

49.

Holzapfel A, Festa A, Stacher-Janotta G, Bergmann H, Shnawa N, Brannath W, et al. Gastric emptying in type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia. 1999;42(12):1410–2. https://doi.org/10.1007/s001250051311.CrossRefPubMed

50.

Laway BA, Malik TS, Khan SH, Rather TA. Prevalence of abnormal gastric emptying in asymptomatic women with newly detected diabetes and its reversibility after glycemic control-a prospective case control study. J Diabetes Complicat. 2013;27(1):78–81. https://doi.org/10.1016/j.jdiacomp.2012.08.001.CrossRefPubMed

51.

Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161(16):1989–96.PubMed

52.

Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97(3):604–11. https://doi.org/10.1111/j.1572-0241.2002.05537.x.CrossRefPubMed

53.

Parthasarathy G, Kudva YC, Low PA, Camilleri M, Basu A, Bharucha AE. Relationship between gastric emptying and diurnal glycemic control in type 1 diabetes mellitus: a randomized trial. J Clin Endocrinol Metab. 2017;102(2):398–406. https://doi.org/10.1210/jc.2016-2809.CrossRefPubMed

54.

Perano SJ, Rayner CK, Kritas S, Horowitz M, Donaghue K, Mpundu-Kaambwa C, et al. Gastric emptying is more rapid in adolescents with type 1 diabetes and impacts on postprandial glycemia. J Clin Endocrinol Metab. 2015;100(6):2248–53. https://doi.org/10.1210/jc.2015-1055.

55.

Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95(1):215–21. https://doi.org/10.1210/jc.2009-1503.

56.

Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91(5):1916–23. https://doi.org/10.1210/jc.2005-2220.

57.

Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785–90. https://doi.org/10.2337/db13-0893.PubMed

58.

Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–5. https://doi.org/10.2337/db10-0474.CrossRefPubMedPubMedCentral

59.

Acosta A, Camilleri M, Burton D, O’Neill J, Eckert D, Carlson P et al. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep. 2015;3(11). doi:https://doi.org/10.14814/phy2.12610.PubMedPubMedCentral

60.

Lorenz M, Pfeiffer C, Steinstrasser A, Becker RH, Rutten H, Ruus P, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. Regul Pept. 2013;185:1–8. https://doi.org/10.1016/j.regpep.2013.04.001.CrossRefPubMed

61.

Jones KL, Rigda RS, Buttfield MDM, Hatzinikolas S, Pham HT, Marathe CS, et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes Obes Metab. 2019;21(5):1158–67. https://doi.org/10.1111/dom.13633.PubMed

62.

Meier JJ, Rosenstock J, Hincelin-Mery A, Roy-Duval C, Delfolie A, Coester HV, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–73. https://doi.org/10.2337/dc14-1984.CrossRefPubMed

63.

Halawi H, Khemani D, Eckert D, O’Neill J, Kadouh H, Grothe K, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890–9. https://doi.org/10.1016/S2468-1253(17)30285-6.

64.

Jones KL, Huynh LQ, Hatzinikolas S, Rigda RS, Phillips L, Pham HT, et al. Effect of exenatide once-weekly (QW) on gastric emptying in health: impact on glycaemia and glucose absorption [abstract]. Diabetologia. 2019;62(Suppl):S377.

65.

Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–9. https://doi.org/10.1111/dom.13120.CrossRefPubMed

66.

Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans-a randomised, controlled study. Aliment Pharmacol Ther. 2012;36(4):379–90. https://doi.org/10.1111/j.1365-2036.2012.05198.x.CrossRefPubMed

67.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes. 2007;56(5):1475–80. https://doi.org/10.2337/db07-0136.CrossRefPubMed

68.

Stevens JE, Buttfield M, Wu T, Hatzinikolas S, Pham H, Lange K, et al. Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes. Diabetes Obes Metab. 2019. https://doi.org/10.1111/dom.13864.PubMed

69.

Nonaka T, Sekino Y, Iida H, Yamada E, Ohkubo H, Sakai E, et al. Early effect of single-dose sitagliptin administration on gastric emptying: crossover study using the (13)C breath test. J Neurogastroenterol Motil. 2013;19(2):227–32. https://doi.org/10.5056/jnm.2013.19.2.227.PubMedPubMedCentral

70.

Nauck MA, Kind J, Kothe LD, Holst JJ, Deacon CF, Broschag M, et al. Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes. 2016;65(8):2440–7. https://doi.org/10.2337/db16-0107.CrossRefPubMed

71.

Wu T, Bound MJ, Zhao BR, Standfield SD, Bellon M, Jones KL, et al. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care. 2013;36(7):1913–8. https://doi.org/10.2337/dc12-2294.PubMedPubMedCentral

72.

Aulinger BA, Bedorf A, Kutscherauer G, de Heer J, Holst JJ, Goke B, et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. 2014;63(3):1079–92. https://doi.org/10.2337/db13-1455.CrossRefPubMed

73.

Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278(6):G946–51. https://doi.org/10.1152/ajpgi.2000.278.6.G946.CrossRefPubMed

74.

Kong MF, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40(1):82–8. https://doi.org/10.1007/s001250050646.CrossRefPubMed

75.

Kong MF, Stubbs TA, King P, Macdonald IA, Lambourne JE, Blackshaw PE, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41(5):577–83. https://doi.org/10.1007/s001250050949.PubMed

76.

Hinshaw L, Schiavon M, Dadlani V, Mallad A, Dalla Man C, Bharucha A, et al. Effect of Pramlintide on postprandial glucose fluxes in type 1 diabetes. J Clin Endocrinol Metab. 2016;101(5):1954–62. https://doi.org/10.1210/jc.2015-3952.

77.

Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151(1–3):123–9. https://doi.org/10.1016/j.regpep.2008.07.003.PubMed

78.

Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014;109(3):375–85. https://doi.org/10.1038/ajg.2013.453.CrossRefPubMed

79.

McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–7. https://doi.org/10.2337/diacare.6.5.463.CrossRefPubMed

80.

Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7(1):25–32.PubMed

81.

Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–622.PubMed

82.

Al-Saffar A, Lennernas H, Hellstrom PM. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroenterol Motil. 2019:e13617. doi:https://doi.org/10.1111/nmo.13617.

83.

Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil. 2014;26(4):521–8. https://doi.org/10.1111/nmo.12296.CrossRefPubMed

84.

McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther. 1991;258(1):136–42.PubMed

85.

Heckert J, Parkman HP. Therapeutic response to domperidone in gastroparesis: a prospective study using the GCSI-daily diary. Neurogastroenterol Motil. 2018;30(1). doi:https://doi.org/10.1111/nmo.13246.

86.

Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil. 2010;16(4):407–13. https://doi.org/10.5056/jnm.2010.16.4.407.CrossRefPubMedPubMedCentral

87.

Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies N Engl J Med. 1990;322(15):1028–31. https://doi.org/10.1056/NEJM199004123221502.CrossRefPubMed

88.

McCallum RW, Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis-a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;26(8):1121–30. https://doi.org/10.1111/j.1365-2036.2007.03461.x.CrossRefPubMed

89.

McCallum RW, Cynshi O. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther. 2007;26(1):107–16. https://doi.org/10.1111/j.1365-2036.2007.03346.x.CrossRefPubMed

90.

Hellstrom PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, et al. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol. 2016;173(11):1768–77. https://doi.org/10.1111/bph.13475.CrossRefPubMedPubMedCentral

91.

Tack J, Rotondo A, Meulemans A, Thielemans L, Cools M. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. Neurogastroenterol Motil. 2016;28(4):487–97. https://doi.org/10.1111/nmo.12736.CrossRefPubMed

92.

Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. https://doi.org/10.1111/nmo.13302.CrossRefPubMedPubMedCentral

93.

Carbone F, Rotondo A, Andrews CN, Holvoet L, Van Oudenhove L, Vanuytsel T, et al. A controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology. 2016;150(4):S213–S4. https://doi.org/10.1016/s0016-5085(16)30792-2.CrossRef

94•.

. Abell T, Kuo B, Esfandyari T, Canafax D, Camerini R, Grimaldi M et al. Velusetrag improves gastoparesis both in symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis in a 12-week global phase 2B study. Gastroenterology. 2019;156(6):S-164. Doi:https://doi.org/10.1016/s0016-5085(19)37201-4. The study reports the results of a newer pharmacologic agent for gastroparesis of which larger studies are in process.

95.

Wo JM, Ejskjaer N, Hellstrom PM, Malik RA, Pezzullo JC, Shaughnessy L, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Aliment Pharmacol Ther. 2011;33(6):679–88. https://doi.org/10.1111/j.1365-2036.2010.04567.x.CrossRefPubMed

96.

Ejskjaer N, Wo JM, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25(2):e140–50. https://doi.org/10.1111/nmo.12064.CrossRefPubMed

97.

McCallum RW, Lembo A, Esfandyari T, Bhandari BR, Ejskjaer N, Cosentino C, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25(11):e705–17. https://doi.org/10.1111/nmo.12184.

98.

Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016;151(1):87–96. https://doi.org/10.1053/j.gastro.2016.03.038.PubMed

99•.

. Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology. 2017;153(5):1240-50 e2. Doi:https://doi.org/10.1053/j.gastro.2017.07.035. The study reports the results of a newer pharmacologic agent for diabetic gastroparesis of which larger studies are in process. PubMedPubMedCentral

100.

Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Diabetes Ther. 2018;9(Suppl 1):1–42. https://doi.org/10.1007/s13300-018-0454-9.CrossRefPubMedPubMedCentral

Title: Diabetic Gastroparesis and Glycaemic Control
Authors: Ryan Jalleh
Chinmay S. Marathe
Christopher K. Rayner
Karen L. Jones
Michael Horowitz
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Insulins
Hyperglycemia
Scintigraphy
Insulins
Type 2 Diabetes
Published in: Current Diabetes Reports / Issue 12/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1281-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2019

Academic Detailing in the New Era of Diabetes Medication Management

Early-Life Arsenic Exposure, Nutritional Status, and Adult Diabetes Risk

Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients

Glucose Management and the Sex Difference in Excess Cardiovascular Disease Risk in Long-Duration Type 1 Diabetes

Organoids from the Human Fetal and Adult Pancreas

The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage